Imbed Biosciences has been awarded $800,000 in a Commercialization Readiness Pilot (CRP) grant by the National Institute for Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the company announced today.

According to a release, the grant supports late-stage development of a next-generation wound dressing that can kill bacteria hidden inside the biofilms in wounds and accelerate wound healing.

“This new grant will support late-stage development of an advanced version of our FDA-cleared Microlyte Matrix product, which will contain a unique combination of silver and gallium metal ions,” Imbed Biosciences CEO Ankit Agarwal said in a statement.

The biotech company recently completed animal studies under prior Small Business Innovation Research (SBIR) grants from the National Institutes of Health (NIH).